This open-label trial (n=27) investigates how MDMA (105mg/70kg) is metabolised by the body and how differences in genes and sex (male/female) influence this.
A Phase I, non-randomised, single-group study in healthy volunteers to evaluate the roles of CYP2D6, CYP3A4 and CYP1A2 (using dextromethorphan and caffeine probes) and COMT in MDMA metabolism, and to assess gender differences and selected genetic polymorphisms (CYP2D6, COMT, SERT) on MDMA pharmacokinetics and effects.
Participants received a single oral dose of MDMA (1.5 mg/kg reported; registry notes range 75–100 mg). Outcomes include pharmacokinetic measures, metabolic probe responses, and genotype–phenotype associations.
Single-group single-dose MDMA (1.5 mg/kg; reported range 75–100 mg).
Reported range 75–100 mg; also described as ~105 mg for 70 kg; other name: Ecstasy.